Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Glyxambi?

See the DrugPatentWatch profile for Glyxambi

Glyxambi (empagliflozin + linagliptin) is a prescription medication used to improve blood‑glucose control in adults with type 2 diabetes mellitus (T2DM). Below is a quick reference guide—feel free to ask follow‑up questions if you want more detail or specific points.

Category Details
Drug classes 1. Empagliflozin – SGLT‑2 inhibitor (sodium‑glucose co‑transporter‑2)
2. Linagliptin – DPP‑4 inhibitor (dipeptidyl peptidase‑4)
Mechanism of action • Empagliflozin blocks glucose re‑absorption in the proximal renal tubules, leading to glucosuria and a mild reduction in plasma glucose.
• Linagliptin increases endogenous GLP‑1 levels, enhancing insulin secretion and suppressing glucagon, especially post‑prandially.
Indication Adjunct to diet and exercise for adults with T2DM when glycaemic control is not adequate on metformin or other oral agents. Not recommended for type 1 diabetes or for diabetic ketoacidosis.
Typical dosing 1 tablet once daily (typically at breakfast). Dose adjustment may be required for renal function:
• eGFR ≥ 30 mL/min/1.73 m²: 1 tablet daily.
• eGFR < 30 mL/min/1.73 m²: not recommended.
Common side effects • Genitourinary infections (vaginal yeast, urinary tract infections) – due to increased glucosuria.
• Mild genital pruritus.
• Mild hypotension/orthostatic dizziness (especially in the first 2–3 weeks).
• Increased urination.
• Mild gastrointestinal symptoms (nausea, diarrhoea).
Serious risks • Genital mycotic infections: treat early with antifungals.
• Diabetic ketoacidosis (DKA) – rare but can occur even with normal blood glucose levels; watch for nausea, vomiting, abdominal pain, or shortness of breath.
• Volume depletion – monitor blood pressure and hydration status.
• Renal impairment – monitor eGFR.
Drug interactions • Diuretics: additive volume‑depleting effects.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce renal perfusion.
• Other glucose‑lowering agents: risk of hypoglycaemia (especially insulin or sulfonylureas).
• ACE inhibitors/ARBs: may worsen renal function; monitor.
Special populations • Pregnancy: Category D; avoid unless no alternative.
• Breastfeeding: Limited data—consult a healthcare professional.
Monitoring • HbA1c every 3 months (or as per provider).
• eGFR, serum creatinine at baseline and then every 6 months (or more frequently if renal function declines).
• Blood pressure monitoring, especially in the first few weeks.
Lifestyle tips • Keep good genital hygiene and dry the area thoroughly to reduce infection risk.
• Stay hydrated; increase fluid intake if you experience increased urination.
• Watch for signs of dehydration—especially during hot weather or intense exercise.

Quick FAQs

  • How does it compare with other dual‑agent combos?
    Glyxambi is one of several fixed‑dose combinations of an SGLT‑2 inhibitor and a DPP‑4 inhibitor. It offers the convenience of a single pill, but each class has its own side‑effect profile; some patients tolerate one more than the other.

  • What if I miss a dose?
    Take it as soon as you remember on the same day. Do not double‑dose. If you forget more than 24 h, skip the missed dose and resume the regular schedule.

  • Can I use it with metformin?
    Yes, Glyxambi is often added to metformin when additional glucose control is needed. Dose adjustments should be guided by your provider.

  • Is it safe in kidney disease?
    Not recommended when eGFR is below 30 mL/min/1.73 m². Your clinician will monitor kidney function closely.

Feel free to let me know if you’d like deeper dives into any of the points above, or if you’re curious about patient experiences, cost/insurance coverage, or research studies.



Other Questions About Glyxambi :

Glyxambi empagliflozin linagliptin fda approval date? Glyxambi harga? Does medicare cover glyxambi? How much is glyxambi without insurance? Glyxambi price in india? Glyxambi 25/5 price mercury drug? Glyxambi 25 5 price mercury?

AI-Drug Label Prescribing Information Alignment Report

62
62%
Grade C

Partial

Mostly Aligned

Patient Risk: Low

Summary

Some major labeling elements are consistent (indication as adjunct to diet/exercise, combination composition, and several serious adverse reactions/warnings). However, multiple claims are not supported by the provided label excerpts, including specific patient selection criteria, approval date, multiple purported 'common' side effects, the incretin-mechanism details, kidney-problem side-effect, and some concomitant-use statements (e.g., with metformin).

Category Scores

Indication
75
Good
Dosage
0
Partial
Warnings
70
Good
AdverseReactions
55
Partial

Accurate Statements

Glyxambi is a prescription medication used to improve glycemic control in adults with type 2 diabetes mellitus.
1 INDICATIONS AND USAGE (adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus)
Glyxambi is a combination drug containing two active ingredients: empagliflozin and linagliptin.
11 DESCRIPTION (contains empagliflozin and linagliptin)
Glyxambi lowers blood glucose levels through two distinct mechanisms.
Partially supported by 1 INDICATIONS AND USAGE and 11 DESCRIPTION (combination of two components; detailed two-mechanism claim not substantiated in provided excerpts)
Empagliflozin, a component of Glyxambi, belongs to the class of sodium-glucose cotransporter-2 (SGLT2) inhibitors.
5 WARNINGS AND PRECAUTIONS (5.1) (references SGLT2 inhibitors and empagliflozin as a component)
Linagliptin, a component of Glyxambi, is a dipeptidyl peptidase-4 (DPP-4) inhibitor.
5 WARNINGS AND PRECAUTIONS (5.7) (references DPP-4 inhibitors in context of linagliptin)
More serious side effects associated with Glyxambi can include pancreatitis.
5 WARNINGS AND PRECAUTIONS (5.2) and 6 ADVERSE REACTIONS (Pancreatitis)
More serious side effects associated with Glyxambi can include severe allergic reactions.
5 WARNINGS AND PRECAUTIONS (5.7) and 6 ADVERSE REACTIONS (Hypersensitivity Reactions)
More serious side effects associated with Glyxambi can include hypoglycemia (low blood sugar).
5 WARNINGS AND PRECAUTIONS (5.5) and 6 ADVERSE REACTIONS (Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues)
More serious side effects associated with Glyxambi can include ketoacidosis.
5 WARNINGS AND PRECAUTIONS (5.1) and 6 ADVERSE REACTIONS (Diabetic Ketoacidosis...)
Glyxambi is itself a combination of two medications.
11 DESCRIPTION (contains empagliflozin and linagliptin) and 1 INDICATIONS AND USAGE (combination product)
Glyxambi can be prescribed in addition to other diabetes treatments, such as insulin.
5 WARNINGS AND PRECAUTIONS (5.5) (addresses concomitant use with insulin)

Unsupported Statements

Glyxambi is prescribed as an adjunct to diet and exercise for adults with type 2 diabetes who have not achieved target blood sugar levels with either empagliflozin or linagliptin alone.
Provided label excerpt for Indications states adjunct to diet/exercise to improve glycemic control in adults with type 2 diabetes, but does not specify failure of prior empagliflozin or linagliptin monotherapy.
Glyxambi is prescribed as an adjunct to diet and exercise for adults with type 2 diabetes when metformin is contraindicated or not tolerated.
No such metformin-conditional indication language appears in the provided Indications excerpt.
Linagliptin increases levels of incretin hormones.
No incretin hormone content is provided in the available label excerpts.
Incretin hormones stimulate the pancreas to release insulin.
No incretin mechanism content is provided in the available label excerpts.
Incretin hormones reduce the liver's production of sugar.
No incretin mechanism content is provided in the available label excerpts.
Glyxambi was approved by the U.S. Food and Drug Administration in May 2015.
No FDA approval date information is present in the provided label sections.
Common side effects of Glyxambi include upper respiratory tract infection.
The provided Adverse Reactions content does not list upper respiratory tract infection or support 'common side effects' for this item.
Common side effects of Glyxambi include urinary tract infection.
The provided list references genitourinary infections, but does not specifically support 'urinary tract infection' as a common side effect.
Common side effects of Glyxambi include stuffy or runny nose.
Not supported by the provided Adverse Reactions excerpts.
Common side effects of Glyxambi include sore throat.
Not supported by the provided Adverse Reactions excerpts.
More serious side effects associated with Glyxambi can include kidney problems.
The provided Adverse Reactions/Warnings excerpts do not support 'kidney problems' as a stated serious adverse reaction.
Glyxambi can be prescribed in addition to other diabetes treatments, such as metformin.
No statement in the provided excerpts addresses concomitant use with metformin.

Contradictions

Important Omissions

Dosage and administration guidance (e.g., dosing regimen, titration, renal-function-based dosing/adjustments) was not provided in the evaluated excerpts.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The response includes several serious adverse reactions/warnings that are supported by the provided label excerpts (pancreatitis, hypersensitivity, hypoglycemia with insulin/secretagogues, and ketoacidosis). However, multiple unsupported claims could misinform patient selection or expectation of adverse events (e.g., specific indicated populations, approval date, multiple 'common' side effects, and 'kidney problems').

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Aligned

Primary Issue
Several substantive claims are not supported by the provided label excerpts, including detailed indication qualifiers, incretin-mechanism assertions, approval date, and multiple purported 'common' adverse effects.

Suggested Improvement
Limit claims to the text actually supported by the provided label excerpts (e.g., indication as adjunct to diet/exercise; composition; supported warnings/adverse reactions). Remove or rephrase unsupported items such as metformin-specific indication/concomitant use, incretin hormone mechanism statements, FDA approval month/year, and the specific 'common' side effects list not present in the excerpts.

Drug Brand Mention Assessment

Branding Score
71
Visibility
76
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

combination drug containing two active ingredients: empagliflozin and linagliptin

Core Claims
  • Glyxambi is a prescription medication used to improve glycemic control in adults with type 2 diabetes mellitus
  • It is a combination drug containing two active ingredients: empagliflozin and linagliptin
  • It is prescribed as an adjunct to diet and exercise for adults with type 2 diabetes
  • The empagliflozin component is an SGLT2 inhibitor that increases glucose excretion in the urine
  • Linagliptin is a DPP-4 inhibitor that increases incretin hormones to stimulate insulin release and reduce liver sugar production
Differentiators
  • Combination of empagliflozin and linagliptin
  • Contains an SGLT2 inhibitor (empagliflozin) and a DPP-4 inhibitor (linagliptin)
  • Used when target blood sugar levels are not achieved with empagliflozin or linagliptin alone
  • Can be used when metformin is contraindicated or not tolerated
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
metformin 33%
50 #5 No
insulin 31%
50 #6 No